BioSpace News Archive

CB2 Insights Inc. (“ CB2 ” or the “ Company ”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q2 2020 earnings call on Tuesday, September 1 st , 2020 at 9:00 a.m. Eastern Daylight Time (EDT). CB2 will issue a press release and file its interim financial statements and interim Quarterly Management Discussion and Analysis (“MD&A”) for the quarter ended June 30, 2020 (the “Q1 2020 Filings”) after the close of markets on August 31 st , 2020. C

Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors

Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates

Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the initiation of a Phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease.

Use of MammaPrint genetic assay alongside clinical assessment is cost-effective versus clinical assessment alone

Gerald Moeller, Ph.D., Elected Chairman of Supervisory Board; Rainer Strohmenger, MD, and Shinichiro Fuse, Ph.D., Named Supervisory Board Members

Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.

The new Company, spearheaded by Michael Davidson, MD and John Kastelein, MD, PhD, FESC, is currently working with the U.S. Food and Drug Administration on a comprehensive Phase 3 clinical development program, including a cardiovascular outcome trial for obicetrapib.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it will host a virtual KOL meeting on Wednesday, September 16th, 2020 from 10:30 am-12 pm ET to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dale joins Kura most recently from Kyowa Kirin, where he served as Senior Vice President and Global Head of Medical Science with a primary focus in oncology. “I am delighted that Stephen is joining Kura to le